- February 15, 2019
Orchard Looks toward Harvesting Expanded Gene Therapy Pipeline – Global Genes
It was about ten months ago that Orchard Therapeutics acquired the gene therapy portfolio of GSK, expanding its pipeline and giving it its first approved therapy. We spoke to Orchard CEO Mark Rothera about his company’s approach to gene therapy, its pipeline, and what he sees as the biggest challenges as Orchard moves towards commercializing
- February 8, 2019
Bring on the gluten: Vaccine offers celiac relief
NEW YORK (NBC News) A peek inside the Friednman family’s kitchen leaves one seeing double. There are two microwaves, two toasters and two different pantries. It’s how the family separates the family’s meals from the gluten-free foods necessary for their 15-year-old son Tyler, who has celiac disease. “He can go in there and get a snack and not have to read every label and worry about things,” Wendy Friedman says.
- January 31, 2019
The Blockbuster Is Dead. Long Live the Blockbuster!
“The definition of blockbuster is changing,” Fouzia Laghrissi-Thode, MD, chief executive officer of DalCor Pharmaceuticals, tells GEN. “Now it’s not necessarily just a dollar sign [in front of a revenue figure] that determines a blockbuster.” As drug development and regulatory reviews become more efficient, she suggests, lesser revenues can generate blockbuster-scale returns on investment.
- January 31, 2019
OncoCyte soars after promising results from its cancer detection tests
Biotech company OncoCyte is using a liquid biopsy to detect lung cancer that is showing promising results. Yahoo Finance’s Alexis Christoforous speaks to William Annett, the CEO of Oncocyte.
- January 30, 2019
These pricey new cancer therapies are custom-made. Can they ever be more mainstream?
It’s the ultimate example of personalized medicine — for some cancer patients who have run out of options, scientists can extract their immune cells and genetically re-engineer them to fight against the tumors.
- January 29, 2019
Liquid biopsy maker OncoCyte shares skyrocket on validation data
A set of positive results validating OncoCyte’s liquid biopsy test has bolstered its stock $OCX, up 221% at press time. DetermaVu scored on both sensitivity — capacity to detect true positives — and specificity, the ability to snuff out negatives, in a blinded trial that involved 250 blood samples from lung cancer patients.
- January 29, 2019
Tiny Health Stock Triples After Lung Cancer Test Wins Wall Street Praise
Micro-cap diagnostic company OncoCyte Corp tripled intraday after announcing break-through results for its lung cancer test that won praise from Wall Street. The company’s R&D validation study of DetermaVu, a non-invasive blood test, “significantly outperforms any other previous blinded study of its kind and signifies the first blood based test on the market to use strictly biomarkers for cancer detection,” Janney analyst Paul Knight proclaimed in a note upgrading his rating of shares to buy from neutral.
- January 18, 2019
Isofol to the rescue in mCRC as folate-based candidate seeks to boost SOC
Isofol Medical AB, a small Swedish company founded a decade ago, is seeking to improve the standard of care (SOC) for metastatic colorectal cancer (mCRC), an oncology indication that receives far less attention than metastatic forms of more prevalent breast, prostate and lung cancers, said CEO Anders Rabbe.
